TransCode shares rise 10.08% premarket after TTX-MC138 enters Phase 2a trial with Quantum Leap following positive Phase 1a results.

TransCode Therapeutics (NASDAQ: RNAZ) surged 10.08% in premarket trading following the announcement of a collaboration with Quantum Leap Healthcare Collaborative to advance its lead candidate, TTX-MC138, into a Phase 2a dose-expansion trial. The trial will evaluate TTX-MC138 in patients with colorectal cancer and minimal residual disease (MRD), a setting where the drug’s mechanism targeting microRNA-10b may prevent metastasis recurrence. Positive safety and efficacy data from the Phase 1a trial, including durable anti-tumor effects and an excellent safety profile, underpinned the decision to progress to Phase 2a. The partnership, part of the I-SPY platform, aims to accelerate precision therapies for high-risk cancers, aligning with TransCode’s focus on first-in-class RNA therapeutics. The news highlights the drug’s potential to address an unmet need in early intervention, bolstering investor confidence in its clinical and commercial prospects.